SpyGlass Pharma Announces Positive 4-Year Data From First-in-Human Trial of Its Innovative BIM-IOL System
SpyGlass Pharma reported positive 4-year results from its first-in-human trial of the BIM-IOL System in glaucoma patients undergoing cataract surgery. Across 21 evaluable patients, mean IOP fell 37% (25.1 to 15.9 mmHg), 86% of patients remained off all IOP-lowering drops, and 90% maintained ≥20/25 vision with no product-related adverse events.
Key figures
- Drug Name
- Bimatoprost Drug Pad-IOL System (BIM-IOL System)
- Phase Of Trial
- First-in-human (Phase 3 trials ongoing)
- Iop reduction
- 37%
- Evaluable patients
- 21
- Month48 mean iop mm Hg
- 15.9 ± 2.8
- Baseline mean iop mm Hg
- 25.1 ± 2.5
- Followup duration years
- 4
- Patients off topical drops
- 86%
- Patients bcdva 20 25 or better
- 90%
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.